Oak Thistle LLC Takes Position in Danaher Co. (NYSE:DHR)

Oak Thistle LLC acquired a new stake in Danaher Co. (NYSE:DHR) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 1,451 shares of the conglomerate’s stock, valued at approximately $363,000.

Several other hedge funds also recently modified their holdings of the stock. Patrick M Sweeney & Associates Inc. grew its position in Danaher by 3.4% during the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock valued at $307,000 after acquiring an additional 40 shares during the last quarter. Trust Co of Kansas boosted its stake in shares of Danaher by 4.1% during the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after purchasing an additional 40 shares during the period. Abacus Planning Group Inc. boosted its stake in shares of Danaher by 0.7% during the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after purchasing an additional 40 shares during the period. ST Germain D J Co. Inc. boosted its stake in shares of Danaher by 1.4% during the first quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock valued at $719,000 after purchasing an additional 41 shares during the period. Finally, Premier Path Wealth Partners LLC boosted its stake in shares of Danaher by 1.8% during the second quarter. Premier Path Wealth Partners LLC now owns 2,345 shares of the conglomerate’s stock valued at $586,000 after purchasing an additional 42 shares during the period. Institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Bank of America increased their price objective on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. TD Cowen increased their price objective on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Leerink Partners increased their price objective on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Evercore ISI dropped their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Finally, Barclays raised their price target on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $278.94.

Insider Buying and Selling

In related news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $8,229,254.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is owned by corporate insiders.

Danaher Price Performance

Shares of NYSE:DHR opened at $273.09 on Tuesday. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The business has a fifty day moving average price of $261.87 and a 200-day moving average price of $255.96. The company has a market capitalization of $197.23 billion, a PE ratio of 46.29, a PEG ratio of 4.38 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the company earned $2.05 earnings per share. The company’s revenue was down 2.9% on a year-over-year basis. As a group, equities analysts expect that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.